Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Giant Cell Arteritis
NCT00076726Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2003
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Infliximab + Prednisone with Placebo + Prednisone (2 arms). Primary endpoint: Proportion of relapse-free patients at 22 weeks. Started Nov 2003; status: terminated.
02
Drugs
infliximab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT00076726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076726.